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Abstract Drug resistance remains a major challenge in
the treatment of patients with ovarian cancer. Therefore,
the development of new anticancer drugs is a clinical
priority to develop more effective therapies. New ap-
proaches to improve clinical outcomes and limit the
toxicity of anticancer drugs focus on chemoprevention.
The aim of this study was to determine the effects of
dendrosomal nanocurcumin (DNC) and oxaliplatin
(Oxa) and their combination on cell death and apoptosis
induction in human ovarian carcinoma cell lines ana-
lyzed by MTT assay and flow cytometry, respectively.
The synergism effect of Oxa and DNC was analyzed
using the equation derived from Chou and Talalay. In
addition, real-time PCR was used to measure the effect
of this combination on the expression levels of long
non-coding RNAs with different expression in ovarian
cancer and normal ovaries. Our data showed that the
effect of DNC on cell death is more than curcumin alone
in the same concentration. The greatest cell death effect
was observed in combination of Oxa with DNC, while
Oxa was added first, followed by DNC at 4 h interval
(0/4 h). The findings indicated that DNC induced apo-
ptosis significantly in both cell lines as compared to
control groups; however, combination of both agents
had no significant effect in apoptosis induction. In ad-
dition, combination of both agents significantly affects
the relative expression of long non-coding RNAs inves-
tigated in the study as compared with mono therapy.
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Introduction
Ovarian cancer is the most common and fatal gyneco-
logical cancer and the fifth leading cause of cancer-
related deaths among women worldwide (Ferlay et al.
2010; Siegel et al. 2016). The poor prognosis of ovarian
cancer is due to the high proportion of cases diagnosed
in the late stage. Despite good response to first-line
chemotherapy drugs, 80% of patients eventually
progressed to advanced stage, and there is currently no
effective treatment (Kim et al. 2011).
Oxaliplatin (Oxa) is a third generation of platinum
drug that is used clinically alone or in combination with
other drugs to treat patients with advanced ovarian
cancer (Machover et al. 1996). Like other platinum
drugs, Oxa has a higher efficiency in combination with
non-platinum drugs such as 5-fluorouracil (5-FU).
However, even with such combinatorial approaches,
some adverse side effects are unavoidable (Kelland
2007).
One approach to improving the efficacy of anticancer
regimens could be to combine conventional chemother-
apeutic agents with natural phytochemical compounds
(Bekaii-Saab et al. 2008; He et al. 2017). In this regard,
chemopreventive phytochemicals could be an emerging
alternative to meet these requirements (Amin et al.
2009).
A growing body of evidence demonstrates the link
between chemoprevention and multiple biological pro-
cesses, including cell cycle arrest and apoptosis, angio-
genesis, and intercellular communication (Howells and
Manson 2005; Aggarwal and Shishodia 2006). Among
them, curcumin (Cur) is a polyphenol derived from the
rhizome of turmeric, which has recently become the
focus of many research fields due to its significant
chemoprevention and chemotherapeutic effects (Jaggi
et al. 2007; Shishodia et al. 2007).
The anticancer property of curcumin was first report-
ed by Kuttan et al. 1987, which showed the effect of
topical application of curcumin to external carcinogen-
esis (Kuttan et al. 1987).
In recent decades, curcumin has successfully demon-
strated the multiple effects of curcumin in a variety of
human clinical trials, including various cancers (Gupta
et al. 2013). However, low bioavailability and poor
pharmacokinetics are major obstacles to the efficacy of
curcumin in vivo (Garcea et al. 2004).
To address this problem, a number of formulations
have been developed, including powders, tablets, cap-
sules, liposomal encapsulation, and nanoparticle
curcumin (Kanai et al. 2012; Naksuriya et al. 2014;
Sasaki et al. 2011). In this regard, curcumin has been
successfully incorporated into dendrosome as a safe and
efficient non-carrier to construct dendrosomal curcumin
(DNC), which has been used in the present study
(Mirgani et al. 2014a).
Long non-coding RNAs (lncRNAs) are longer than
200 nucleotides and play a crucial role in various bio-
logical processes (Spizzo et al. 2012).
Aberrant expression of lncRNAs is closely linked to
the development and progression of tumors after a vari-
ety of experimental studies (Ren et al. 2015). Therefore,
the specific expression of lncRNAs in certain types of
cancer can be diagnosed as tumor markers and also be
used as therapeutic targets for overcoming cancer.
Therefore, the aim of this study was to evaluate the
effects of different concentrations of Oxa, DNC, and
their combinations on viability and apoptosis induction
in OVCAR3 and SKOV3 ovarian cancer cell lines. In
addition, real-time PCRmethods were also performed to
investigate the effect of each agent on the expression
level of selected lncRNAs in the OVCAR3 cell line.
Materials and methods
Agents
The powder of Oxa and Cur was purchased from Sigma-
Aldrich Company, USA. Oxa was initially dissolved in
dimethyl formamide (DMF) followed by dilution with
milli Q (mQ) water (at a ratio 1:5) to produce a 1-mM
stock solution. Cur was dissolved in dimethyl sulfoxide
(DMSO) and ethanol for making 1 mM stock solution.
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Oleoyl chloride, polyethylene glycol 400, chloroform,
and triethylamine that were used for preparation of
dendrosome were from Sigma-Aldrich Company.
Dendrosome (polymeric micelle OA400 carrier)
preparation
Dendrosome nanoparticle specified Dendromer OA400,
a non-ionic biodegradable denderic glycol ester (MW:
590 Da, HLB: 12.5 Mh/M, hydroxyl value: 95 mg
KOH/g, and acid value: mg KOH/g), was a gift from
Institute of Biochemistry and Biophysics, University of
Tehran, Iran (Sarbolouki et al. 2000; Sadeghizadeh et al.
2008). The protocol of dendrosome synthetics has been
described before (Babaei et al. 2012; Erfani-Moghadam
et al. 2014). The OA400 as a carrier was produced with
esterification of oleoyl chloride (0.01 mol) and polyeth-
ylene glycol 400 (0.01 mol) in the presence of
triethylamine (0.012 mol) and they were solved in chlo-
roform at 25 °C for 4 h. After filtration of triethylamine
hydrochloride salt from organic phase, chloroform was
eliminated from OA400 with evaporation in a vacuum
oven at 40 °C for 4 h (data not shown).
DNC preparation
For preparation of DNC, we used the protocol that was
optimized before with our team (Mirgani et al. 2014b).
In this set up, various ratio of dendrosome/Cur (weight/
weight) from 50:1 to 10:1 was tested and then DNC
preparation was done with 25:1 ratio of dendrosome/
Cur (Babaei et al. 2012). For analyzed absorbance spec-
tra of Cur by ultraviolet spectrophotometry (Infnite®
200 PRO, Tecan, Mannedorf, Switzerland), Cur was
dissolved in different amounts of dendrosome (Babaei
et al. 2012; Alizadeh et al. 2012). Finally, the suitable
mixture of Cur and dendrosome was examined for
excitation/emission value and Cur as the control sam-
ples was dissolved in PBS and 1% methanol. This
method was performed with Gou et al.’s protocol
(Babaei et al. 2012). After this, Cur and dendrosome
were dissolved in 5 mL acetone and this mixture was
added to 5 mL of sterile PBS. After this, acetone was
evaporated in a rotary evaporator. The Cur/dendrosome
micelle solution was sterilized using a 0.22-μm syringe
filter (EMD Millipore) (Gou et al. 2011). After the
completion of DNC, we protected it at 4 °C in far from
of light.
DNC characterization
Some confirmatory test such as HPLC chromatographic
profiles for dendrosome as the carrier, NMR spectrum
and FTIR (Fourier transform infrared) spectrum, also
characteristic factor such as drug loading rate, size that
measured by dynamic light scattering (DLS), superficial
charge have been tested previously and mentioned in
some previous papers of our research group (Babaei
et al. 2012; Erfani-Moghadam et al. 2014; Gou et al.
2011). Results of transmission electron micrographs
confirmed DNC were sphere shaped, curcumin-loaded
concentration was assayed by HPLC-DAD analysis and
the curcumin loading efficiency had been proved to be
very high (87%). To confirm the dendrosomal chemical
structure, spectroscopy analysis was done and chro-
matographic profiles at 240, 330, 420, and 430 nm were
registered. OA400 showed stretching band of C-H ali-
phatic, C-H unsaturated aliphatic, carbonyl group of
ester bands, C-H bending vibration of CH2 and the C-
H bending vibration of CH3 at 2921 cm−1, 3002 cm−1,
1732 cm−1, 1462 cm−1, and 1350 cm−1 respectively
were measured by FTIR spectrum.
Cell culture
The ovarian cancer cell lines OVCAR3 and SKOV3
were generously gifted from Dr. Rabbani’s laboratory
(Avicenna Research Institute) and normal human fibro-
blastic cells (HFSF-PI3) were obtained from the national
cell bank of the Pasteur Institute, Tehran, Iran, and were
cultured in RPMI1640 (Gibco Invitrogen, Basel, Swit-
zerland) and Gibco® Dulbecco’s modified Eagle medi-
um (Life Technologies, Carlsbad, CA, USA), respec-
tively. Cells were supplemented with10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin (100 units/
mL) and maintained at 37 °C with 5% CO2.
Uptake of DNC and empty curcumin in ovarian cancer
cells
Curcumin has natural fluorescent viability with green
spectrum (Anand et al. 2007). In order to determine of
fluorescent viability of DNC and confirm the intracel-
lular uptake of it in ovarian cancer cell lines, the 50,000
cells cultured on cover glass (BDBiosciences), in 4-well
plates until confluency of cells reached to 70% in next
day.
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Then, the wells were treated with 20 μM curcumin in
carrier of dendrosome (DNC) and empty curcumin with
same concentration and empty dendrosome also, for
every condition we used 3 wells and then the cells
checked in 1 and 2 h after treatment with Nikon (TI-
DS 30W) fluorescent microscope. This process was
done triplicate separately.
Cell viability assay
Ce l l v i a b i l i t y wa s e v a l u a t e d b y 3 - ( 4 , 5 -
dimethylthiazole-2-yl)-2, 5-diphenyltetrazolium bro-
mide (MTT) assay. In brief, 10,000 to 20,000 cells/
well were seeded into a 96-well plate in RPMI-1640
medium and allowed to attach overnight. We used 3
wells for every condition and cells were treated with
DNC, Oxa and combination of them at different con-
centrations and incubated for 24, 48, and 72 h (37 °C,
5% carbon dioxide in air), all experiments were car-
ried out separately in triplicate.
For the combination experiments, DNC and Oxa
were added at a constant ratio according to checker-
board assay (based on IC50 values). Cell growth inhi-
bition was determined using the MTT assay. Hence, the
medium was removed and 20 μl of the MTT (5 mg/mL)
(Sigma, St. Louis, MO, USA) was added to each well of
96-well plate and incubated for 4 h at 37 °C. After this,
the crystals were dissolved by 150 μl of DMSO which
added to each well. Absorbance was measured with
microplate reader at 570 nm.
The effect of each compound or drug treatments
that used single or in combination on growth inhibi-
tion was assessed as the percentage of inhibition rel-
ative to the untreated controls (100%). The combina-
tion effect of DNC and Oxa was calculated based on
CI as a combination index (Chou and Talalay 1984;
Chou 1974):
Synergism, additivity, or antagonism effect was eval-
uated with the combination index (CI) calculated by the
Chou-Talalay equation. A CI < 0.9, CI = 0.9–1.2, and
CI > 1.2 demonstrated synergistic, additive, or antago-
nistic effect, respectively.
CI = D1/D1X + D2/D2X
Where D1 and D2 are doses of compounds 1 and 2 in
combination to achieve x% inhibition, while D1x and
D2x in the denominator represent doses of compounds 1
and 2 to achieve x% inhibition when present alone
(Chou 1976).
Apoptosis detection
Annexin-V-FLUOS and PI staining kit (Roche Ap-
plied Science, Penzberg, Germany) was used for ap-
optosis detection following the manufacturer’s in-
struction. Approximately, 0.5 × 106 cells/well of
SKOV3 and OVCAR3 cells were seeded onto 6-well
plates and all of the treatments were done 3 times
separately. After 24 h, cells were treated with 18 and
12 μM of DNC for 24 and 48 and only 12 μM for 72 h
and SKOV3 cells with 20 and 17.5 μM of DNC for 24
and 48 and 17.5 μM for 72 h of DNC for 24, 48, and
72 h. Cells were trypsinized and centrifuged at 200g
for 5 min. The cell pellet was washed with PBS buffer
and resuspended in 100 μL Annexin-V-FLUOS bind-
ing kit (Roche Applied Science, Penzberg, Germany
cat number: 858777001), incubated for 10–15 min at
15–20 °C and immediately analyzed by FACSCalibur
flow cytometer. This protocol was repeated with
IC20% of DNC, Oxa and combination of them in
48 h for checking combination thereof.
Quantitative RT-PCR assay
To determine the effect of DNC, Oxa (24 and 48 h
after treatment) and combination of them (48 h after
treatment) on the panel of lncRNAs expression,
OVCAR3 cells (1 × 105 cells per well) seeded in 6-
well plates and treated with 5 μM of DNC with 4.5 μg
of Oxa. We carried out every condition in triplicate
separately. Untreated cells attended as controls. Total
RNAwas isolated using TRIzol® reagent (Life Tech-
nologies) followed by DNase I digestion (Thermo
Fisher Scientifc, Waltham, MA, USA). Complemen-
tary DNA was synthesized by PrimeScript™ RT re-
agent kit (Takara Bio Inc., Shiga, Japan). Reverse
transcription was carried out using 500 ng of total
RNA following to the manufacturer’s protocol and
2 μl of the synthetized cDNA was used to perform
real-time PCR by IQ5 (Biorad, Germany) using
SYBR green master mix (Biofact, Corea) in a total
reaction volume of 10 μl. The sequences of specific
primers were shown in Table 1.
The changes in long non-coding RNA expression
were normalized by that of GAPDHmRNA expression.
The data was analyzed using 2−ΔΔct.
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Statistical analysis
Statistics were presented in Prism® 5 software
(GraphPadSoftware, Inc., La Jolla, CA, USA) and ana-
lyzed using one-way ANOVA analysis of variance
followed by Tukey’s HSD multiple comparison test.
Differences among groups were stated to be statistically
significant when P < 0.05.
Results
Cellular uptake of DNC and curcumin
In order to determine cellular uptake of DNC in ovarian
cancer cells and comparison with Cur, OVCAR3 and
SKOV3 cells were treated with DNC, Cur and
dendrosome for 1 and 2 h. Our results revealed that
fluorescence intensity of Cur in DNC was more than
Cur alone and no fluorescence activity detected for
dendrosome and control group without any treatment
(Fig. Fig. 1).
DNC induces cell death in OVCAR3 and SKOV3
in a time- and dose-dependent manner
The sensitivity of SKOV3 and OVCAR3 cells to DNC,
free Cur, and empty dendrosome were studied using
MTT assay. For this purpose, we used free Cur and
DNC (containing the same concentration of Cur) and
similar concentration of dendrosome that used in DNC
as a carrier. As shown in Fig. Fig. 2, DNC significantly
suppressed the proliferation of SKOV3 and OVCAR3
cells in a time- and dose-dependent manner. The half
maximal inhibitory concentration (IC50) of DNC for
SKOV3 cells was 25 μM after 24 h (Fig. Fig. 2a) and
22 μM after 48 h (Fig. Fig. 2b), which declined to
17.5 μM at 72 h (Fig. Fig. 2c) (P ≤ 0.001) and 20 μM
after 24 h, 15 μM after 48 h and 10 μM after 72 h in
OVCAR3 respectively (data in supplementary). On the
other hand, no significant inhibitory effect was observed
for dendrosome alone (in concentration near the IC50
and under IC50 that was used) and inhibitory effect of
free Cur was fewer than DNC in equal concentration. In
total, these findings demonstrated that dendrosome in-
creased the water solubility and entry of Cur to cells
without any significant toxic effects related with
dendrosome as a carrier in concentration below IC50
in this period of times.
Oxa induces cell death in OVCAR3 and SKOV3
in a time- and dose-dependent manner
Oxa induced cell death in dose-dependent manner in
OVCAR3 and SKOV3 cell lines. Inhibitory concentra-
tion of 50% of cells (IC50) of Oxa in OVCAR3 cells
Table 1 List of specific primers used in real-time polymerase chain reaction assay
Gene Designed oligonucleotide Amplicon length (bp)
XIST TTCATTGTTCCTATCTGCCAAATC 152
CTATCCTCAAGTGCTAGAGTGC
MALAT1 GAGCGGAAGAACGAATGTAAC 147
TCATAATCTCCCACCTGTCTAAG
LSINCT5 AGTCCAATAGCATCATAGGTCTG 136
AGCCAAGGTCCCATCAAGG
OVAAL GAAGAATCTGAAGGACAAGTGG 158
ATTATTGGCTGGGTGAAATGC
FAL1 GCCAAGAAGCTCATACTGAC 177
TCCCATTCATACTCAACTCTCC
CCAT2 AGAGGGAGGTATCAACAGAGAC 150
AGAGAACGAGGCTGGGAAAG
ANRIL AACAGCAGAGATCAAAGAAAAGA 145
GGATTCCAGCACACCTAACAG
AB073614 TCTGCTCCTGGGTCTTACAC 168
TCATATTTGGCTCTCTTCACTTTG
GAPDH GAGTCAACGGATTTGGTCGT 237
TTGATTTTGGAGGGATCTCG
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was 15 μM, 12 μM and 10 μM after 24 h, 48 h and 72 h
(Fig. 3a) and for SKOV3 cells were 27.5 μM after 24 h,
25 μM after 48 h and 25 μM after 72 h (Fig. 3b),
respectively (P ≤ 0.001).
The effect of DNC on normal cells
Studying the inhibitory effect of DNC in normal human
fibroblast cells indicated that 25 μM of DNC or less
(near the IC50 of DNC on cancer cell in 24, 48 and 72 h)
was not significant and only killed 16%, 20% and 24%
of normal cells after 24, 48 and 72 h exposure to 35 μM
of DNC respectively, also there is not any significant
difference between DNC and Cur in the same concen-
tration (Fig. Fig. 4). Our findings verified the safety of
25 μM of DNC or less, (the concentration that used for
ovarian cancer cells treatment) in normal human fibro-
blast cells.
Growth-inhibitory effects of drug combinations
Synergism from combination of DNC with Oxa was
examined in the SKOV3 and OVCAR3 cell lines.
Table 2 shows the CIs at IC20, IC50 and IC70 for the
combination of DNC with Oxa in SKOV3 and
OVCAR3 human ovarian cancer cell lines, where
IC20, IC50 and IC70 are the combined drug concentration
required for 20%, 50% and 70% cell death, respectively
(Chou and Talalay 1984). According to our results,
synergistic or additive effect of DNC with Oxa on cell
death was confirmed in different concentrations (Table 2
and Fig. Fig. 5).
Also, we evaluated the effect of different concentra-
tions of DNC and Oxa on cell viability according to the
checkerboard method. For this purpose, we prepared
serial dilution of DNC and Oxa (based on IC50 values)
with constant ratio and found IC20% of DNC and Oxa
that are 5 μM of DNC with 4.5 μg of Oxa in OVCAR3
as well as 10 μM of DNC together with 10 μg of Oxa in
SKOV3 caused 50% of cell death in these cells after
48 h. Of note, for combination studies, we also evaluat-
ed the effect of sequential addition of both agents with
above ratio: simultaneous addition of DNC and Oxa
(0/0 h), Oxa added first (0/4 h) followed by DNC with
4 h gap between both treatments and the converse
(4/0 h) and finally sequential addition with Oxa added
first (0/24 h) followed by DNC using 24 h gap (24/0).
After 48 h of incubation, the results of MTT assay
Fig. 1 Intracellular uptake of 20 μM Cur and DNC in SKOV3 cell line 1 and 2 h after treatment
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Fig. 2 Effects of dendrosomal curcumin, free curcumin, and
empty dendrosome on the viability of SKOV3 cells. Cells were
treated with different concentrations of each agent after (a) 24 h,
(b) 48 h, and (c) 72 h. Notes: Data expressed as mean ± standard
deviation; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 compared to me-
dia and cell as a negative control
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indicated the synergistic effect of Oxa and DNC on
OVCAR3 and SKOV3 cell growth inhibition while the
greatest effect was related to sequential addition with Oxa
added first followed byDNCwith 4 h gap (0/4 h) (Fig. 6).
Effects of DNC and Oxa treatment on apoptosis
induction in ovarian cancer cell lines
To investigate the susceptibility of cells to apoptosis,
OVCAR3 cells were treated with 18 and 12μMofDNC
for 24 and 48 and only 12 μM for 72 h (data in supple-
mentary), whereas, SKOV3 cells treated with 20 and
17.5 μM of DNC for 24 and 48 and 17.5 μM for 72 h.
Our results indicated that apoptosis percentage in-
creased in a dose-dependent manner (p < 0.001) but
the effect of time was not significant in most of the
condition in both cell lines. Also, there was no
significant difference between 17.5 μM of DNC in 48
and 72 h (Fig. 7). Then, we selected 48 h for checking
the effect of DNC, Oxa and combination of them in
apoptosis induction in both cell lines.
For this purpose, the cells were treated with cells with
5 μM of DNC, with 4.5 μg of Oxa in OVCAR3 as well
as 10 μMof DNC together with 10 μg of Oxa in SKOV3
cells and analyzed 48 h after treatment. Although, our
results showed that the combination of DNC and Oxa
increased apoptosis in both cell lines and the effect of
them was not significant in both cell lines (Fig. 8).
Effects of DNC and Oxa treatment on long non-coding
RNA expression
In order to recognize the effect of DNC and Oxa on long
non-coding RNA expression, we selected some of the
Fig. 3 Effect of Oxa on the viability of aOVCAR3 and b SKOV3 cells. Cells were treated with different concentrations of each agent after
24 h, 48 h, and 72 h
Fig. 4 Effect of different concentrations of DNC and Cur on the viability of HFSF-PI3 cells after 24 h, 48 h, and 72 h of treatment
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long non-coding RNAs with different expression levels
in ovarian cancer compared with normal tissue.
OVCAR3 cells were treated with DNC and Oxa alone
at 24 and 48 h and combination of them in 48 h. One-
way ANOVA analysis determined that DNC, Oxa and
combination of them affect majority of long non-coding
RNA expression in OVCAR3 cells in a dose- and time-
dependent manner which has been explained in detail
below (Fig. 9 and Table 3).
LSINCT5 expression was affected by DNC, Oxa
and combination of them in OVCAR3 ovarian cancer
cell line
LSINCT5 expression significantly decreased after
OVCAR3 cell line treatment with DNC and Oxa in 24
and 48 h and combination of them in 48 h. Our results
indicated that the effect of Oxa (0.421, 0.152-fold) was
greater than DNC (0.617, 0.235-fold) in 24 and 48 h,
respectively. Moreover, combination of DNC and Oxa
after 48 h had more inhibitory effect compared with each
of them alone (0.058-fold) but it was not significant
compare to DNC and Oxa after 48 h alone (Fig. 9a).
DNC, Oxa and combination of them decreased CCAT2
expression in OVCAR3 ovarian cancer cell line
CCAT2 expression decreased in OVCAR3 cell line after
treatment with DNC and Oxa in 24 and 48 h. Our results
showed that the effect of Oxa (0.305-fold) was greater
than DNC (0.581-fold) after 24 h. However, the greatest
inhibitory effect was seen in DNC treatment (0.088-
fold) after 48 h as compared with Oxa and combination
of both agents (Fig. 9b).
DNC, Oxa and combination of them downregulated
ABO73614 expression in OVCAR3 ovarian cancer cell
line
ABO73614 expression decreased significantly in
OVCAR3 cell line following treatment with DNC,
Oxa and combination of them. Our results represented
that the effect of Oxa on ABO73614 expression reduc-
tion (0.339-fold in 24 h, 0.11-fold in 48 h) was more than
DNC (0.567-fold in 24 h, 0.198-fold in 48 h). However,
combination treatment with both Oxa and DNC
Table 2 Combination index (CI) value for DNC and Oxa in 48 h after treatment
SKOV3 IC20 IC50 IC70 OVCAR3 IC20 IC50 IC70
DNC (alone) (μM) 10 22 25 DNC (alone) (μM) 5 15 25
DNC (combination) (μM) 5 10 12 DNC (combination) (μM) 2 5 15
Oxa (alone) (μgr) 10 25 42 Oxa (alone) (μgr) 4.5 12 20
Oxa (combination) (μgr) 5 10 20 Oxa (combination) (μgr) 2 4.5 9
CIs ± SD 1 ± 0.09 0.855 ± 0.07 0.95 ± 0.091 CIs ± SD 0.84 ± 0.07 0.708 ± 0.03 1.009 ± 0.17
Fig. 5 Isobologram of combination effect of DNC and Oxa in a OVCAR3 and b SKOV3 cell lines
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decreased ABO73614 expression levels after 48 h more
than that of monotherapy (0.088-fold) (Fig. 9c).
DNC, Oxa and combination of them inhibited ANRIL
expression in OVCAR3 ovarian cancer cell line
ANRIL expression significantly decreased after OVCAR3
cell line treatment with DNC and Oxa in 24, 48 h and
combination of them in 48 h. Our results documented that
the effect of Oxa (0.128 and 0.097-fold) was greater than
DNC (0.316 and 0.151-fold) in 24 and 48 h and combi-
nation of them in 48 h (0.112-fold) (Fig. 9d).
DNC, Oxa and combination of them significantly
increased BC200 expression in OVCAR3 ovarian
cancer cell line
BC200 expression in OVCAR3 cell line significantly
increased 24 and 48 h after treatment with DNC, Oxa, as
well as, in combination of them after 48 h. We noticed
that the effect of Oxa (16.00 and 20.84-fold) was greater
than DNC (5.39 and 17.66-fold) after 24 and 48 h,
respectively. Furthermore, the combination of DNC
and Oxa upregulated BC200 expression in a synergistic
mode after 48 h (25.99-fold) (Fig. 9e).
FAL1 expression was inhibited by DNC, Oxa
and combination of them in OVCAR3 ovarian cancer
cell line
FAL1 expression significantly reduced after OVCAR3
ovarian cancer cell line treatment with DNC, Oxa in 24,
48 h and combination of them in 48 h. We found that
although the effect of Oxa (0.487-fold) was similar to
DNC (0.488-fold) in 24 h, its effect (0.117-fold) was
greater than DNC (0.375-fold) in 48 h. Notably, combi-
nation of both agents has most inhibitory effect in 48 h
(0.045-fold) (Fig. 9f).
MALAT1 expression declined in OVCAR3 ovarian
cancer cell line after treatment with DNC, Oxa
and combination of them
MALAT1expression decreased in OVCAR3 ovarian
cancer cell line after treatment with DNC and Oxa in
24 and 48 h and combination of them in 48 h. Our
data showed that the inhibitory effect of Oxa (0.56
and 0.57-fold) was higher than DNC (0.95 and 0.76-
fold) in 24 and 48 h, respectively. We also found
that combination of DNC and Oxa has synergistic
effect on downregulation of MALAT1 in 48 h
(Fig. 9h).
Fig. 6 The sequential addition effect of Oxo combine with of
DNC (IC50% of cells with combination of them) on a OVCAR3
and b SKOV3 cell viability after 48 h. Note: * DNC or Oxa
compare with different types of combination and negative control
compare with DNC, Oxa and different types of combination #
Combination of DNC and Oxa (DNC +Oxa (4/0)) compare with
other types of combination
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Fig. 7 Apoptosis induction analysis with 17.5 and 20 μM for 24
and 48 h and only 17.5 μM of DNC for 72 h in SKOV3 cell.
Viable cells (annexin-V-/PI-), early apoptotic cells (annexin-V+/
PI-), late apoptotic cells (annexin-V-/PI+), and necrotic cells
(annexin-V+/PI+) are located in the lower left, lower right, upper
right, and upper left. Quadrants, respectively. Notes: Data
expressed as mean ± standard deviation; **P, 0.01; ***P, 0.001
compared to control
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XIST expression was not affected by DNC, Oxa
and combination of them in OVCAR3 ovarian cancer
cell line
DNC, Oxa and combination of them had not significant
effect on XIST expression in OVCAR3 ovarian cancer
cell line in 24 and 48 h (Fig. 9g).
Discussion
Ovarian cancer has been reported as one of the
leading causes of cancer death in women in recent
decades. The poor prognosis of this cancer is due to
the fact that patients are usually diagnosed with
advanced tumors that are less affected by existing
treatment modalities (Testa et al. 2014). Therefore,
the study of molecular events in ovarian cancer is an
important topic that would provide better insights
for improved diagnostic therapeutic interventions
for this disease.
The development of chemotherapeutic agents has
made significant progress in cancer therapy. However,
drug resistance is a major obstacle (Kwon 2014). Resis-
tance to Oxa is a complex process that is caused by
several mechanisms, including the repair of DNA dam-
age, inactivation of the cell death program, dysregula-
tion in signaling pathways, or high detoxification activ-
ity. In this regard, combination therapy has been pro-
posed as an emerging approach to solve this problem
(Martinez-Balibrea et al. 2015). The anticancer activity
of many food-derived compounds has been studied and
has proved to be suitable candidates for combination
therapy with existing chemotherapy drugs. Curcumin is
one of the compounds that has documented anticancer
activity in many cancers.
Fig. 8 DNC, Oxa and combination of them induced apoptosis
using annexin-V-FLUOS/propidium iodide (PI) staining, SKOV3
cells were treated with DNC (5 μM), with Oxa (4.5 μg) and
combination of them after 48 h of treatment and OVCAR3 cells
were treated withDNC (10μM),withOxa (5μg) and combination
of them after 48 h of treatment
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Curcumin has the potential to regulate a variety of
pathophysiological mechanisms including cell cycle
maintenance, carcinogenesis, wound healing, and in-
flammation (Tharakan et al. 2010). Curcumin has also
proved to sensitize human and rat glioma cells for
radiotherapy in T98G, T67 and U87MG cell lines and
to inhibit AP-1 and NF-κB signaling pathways
(Dhandapani et al. 2007). Curcumin harnessed TPA-
stimulated PKC activity in human astroglioma cells
and, as well as, downregulated pro-angiogenic AP-1
and MMP9 (Woo et al. 2005).
In human HCT-116 colon cancer cells, curcumin has
been reported to inhibit PKC activation by control the
release of Ca2+ from the endoplasmic reticulum (Dyer
et al. 2002; Wang et al. 2006). In another study, curcumin
was shown to inhibit carcinogen-induced JNK activation
(Chen and Tan 1998). Curcumin inhibits the proliferation
of LNCaP prostate cancer cells via inhibiting AP-1 tran-
scription factors (Polytarchou et al. 2005). In study con-
ducted by Prusty and Das, it has been presented that
curcumin can downregulate AP-1 in cervical cancer cell
lines (Prusty and Das 2005). Hence, curcumin control
Fig. 9 DNC, Oxa and combination of them affect expression of
different long non-coding RNAs in OVCAR3 cancer cell. a
LSINCT5, b CCAT2, c ABO73614, d ANRIL, f FAL1, and h
MALAT1, significantly downregulated with most of the treatment
compared to the negative control; e BC200 significantly
upregulated with DNC, Oxa and combination of both in 48 h (g)
DNC, Oxa and their combination does not show significant effect
on XIST expression. Notes: Data expressed as mean ± standard
deviation; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 compared to non-
treated cells (media + cell)
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PKC activity by inhibiting pre-angiogenic signaling
through the ERK-AP-1-MMP-9 pathway to inhibit neo-
vascularization in tumors (Heger et al. 2014).
In the DMBA-induced carcinogenic hamster model, a
12-week turmeric diet (1%) reduced DMBA-induced tu-
mor volume by downregulation of p21 (Garg et al. 2008).
Interestingly, when Hepa1–6 cells were transfected with c-
Met-CAT promoter constructs and then stimulated with
HGF, rapid induction of AP-1 DNA binding activity ac-
crued. When these cells were treated with curcumin, the c-
Met promoter activity was removed (Seol et al. 2000).
The role of curcumin in combination with chemother-
apy has been investigated in various in vitro and in vivo
studies. In one study, tumor size and metastatic behavior
were significantly reduced when curcumin was combined
with various chemotherapeutic drugs compared to
monotherapy (Howells et al. 2011). These preclinical data
could provide a theoretical basis for clinical investigations.
There is increasing evidence that lncRNAs are important
regulators of many biological processes and may play a
role in oncogenic or tumor suppressor in a variety of
human cancers (Huarte 2015; Xie et al. 2016).
To the best of our knowledge, this is the first report to
investigate the effect of a chemotherapeutic or chemopre-
ventive agent on the lncRNA expression pattern in ovarian
cancer. In this study, we examined the inhibitory effects of
DNC, free curcumin and empty dendrosome on the growth
of OVCAR3 and SKOV3. Our data proved significant
potential of DNC on cell growth inhibition, while no such
inhibitory effect observed by empty dendrosome.
Consistence with results from previous study carried
out by Babaei et al., our findings also revealed that
Fig. 9 (continued)
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Table 3 The effect of DNC and Oxa and combination of them on expression of different long non-coding RNAs in OVCAR3 cancer cell
Name Condition Fold
change
P value compare
to control
P value compare
to DNC 48 h
P value compare
to Oxa 48 h
Up or
downregulation
LSINCT5 Control 1 – – –
DNC 24 h .617 .013 – – Down
Oxa 24 h .421 .001 – – Down
DNC 48 h .235 .0001 – – Down
Oxa 48 h .152 .0001 – – Down
Combination 48 h .058 .0001 .218 .489 Down
CCAT2 Control 1 – – –
DNC 24 h .58 .039 – – Down
Oxa 24 h .30 .009 – – Down
DNC 48 h .08 .0008 – – Down
Oxa 48 h .29 .003 – – Down
Combination 48 h .11 .005 .94 .03 Down
AB073614 Control 1 – – –
DNC 24 h .56 .03 – – Down
Oxa 24 h .33 .000 – – Down
DNC 48 h .19 .000 – – Down
Oxa 48 h .11 .000 – – Down
Combination 48 h .08 .000 .34 .84 Down
ANRIL Control 1 – – – –
DNC 24 h .31 .009 – – Down
Oxa 24 h .12 .000 – – Down
DNC 48 h .15 .000 – – Down
Oxa 48 h .09 .000 – – Down
Combination 48 h .11 .000 .78 .9 Down
BC200 Control 1 – – –
DNC 24 h 5.4 .026 – – Up
Oxa 24 h 16 .001 – – Up
DNC 48 h 17.66 .000 – – Up
Oxa 48 h 20.84 .000 – – Up
Combination 48 h 25.99 .000 .018 .115 Up
FAL1 Control 1 – – –
DNC 24 h .48 .005 – – Down
Oxa 24 h .48 .005 – – Down
DNC 48 h .37 .002 – – Down
Oxa 48 h .11 .000 – – Down
Combination 48 h .04 .000 .043 .633 Down
XIST Control 1 – – –
DNC 24 h 1.02 .99 – – N/A
Oxa 24 h 1.4 .55 – – Up not significant
DNC 48 h .93 .90 – – N/A
Oxa 48 h 1.13 .86 – – N/A
Combination 48 h .98 .82 .90 .63 N/A
MALAT1 Control 1 – – –
DNC 24 h .95 .83 – – N/A
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inhibitory effect of free curcumin was less than DNC in
equal concentration suggesting that dendrosome in-
creases the water solubility and entry of curcumin to
cells without any toxic effects correlated with
dendrosome as a carrier (Babaei et al. 2012).
To identify the potential synergistic effect of DNC
and Oxa, we developed a timeline for the treatment of
OVCAR3 and SKOV3 with DNC, Oxa, or a combina-
tion of these at varying concentrations and at different
time period (24, 48 and 72 h).
In line with results from other studies (Nessa et al.
2012; Montopoli et al. 2009; Yunos et al. 2011), our data
also showed that exposure of ovarian carcinoma cells to
DNC and Oxa had a greater impact on cell viability than
single agent treatment. In addition, staining cells with
annexin-V and PI showed that both DNC and Oxa
can be sensitive to apoptosis in OVCAR3 and
SKOV3 cells, respectively. However, our combina-
tion approach has no significant synergistic effect in
inducing apoptosis.
To gain insight into the effects of Oxa, DNC, or a
combination thereof on long non-coding RNA gene
expression in OVCAR3 cell lines, we evaluated the
expression levels of a panel of long non-coding RNAs
that have previously been reported for ovarian cancer.
LSINCT5, the stress-regulated lncRNA, is reported
to be dramatically overexpressed in breast and ovarian
cancers. It appears that downregulation of this lncRNA
is attributable in cellular proliferation in breast and
ovarian cancers (Meryet-Figuière et al. 2016).
Stress-regulated lncRNA LSINCT5 has been report-
ed to be significantly overexpressed in breast and ovar-
ian cancer. It appears that downregulation of this
lncRNA can be attributed to cell proliferation in breast
and ovarian cancer (Meryet-Figuière et al. 2016).
Microarray analysis showed that downregulation of
LSINCT5 triggered the deregulation of 816 genes. Of
these, it has been suggested that downregulation of the
CXCR4 gene contributes to cellular proliferation (Silva
et al. 2011).
In view of the potential effect of this lncRNA in
ovarian cancer cells, we have examined in this study the
effect of DNC, Oxa and their combination on the expres-
sion level of LSINCT5 in OVCAR3 cells. According to
our data, the effect of Oxa was more than DNC in reduc-
ing the LSINCT5 expression level. Moreover, the combi-
nation of DNC andOxa had a synergistic inhibitory effect.
The lncRNA CCAT2 (colon cancer-associated tran-
script 2) has been shown to be associated with the
promotion of tumor metastasis, growth and chromosom-
al instability in a variety of cancers. Recent data pub-
lished in a study on CCAT2 expression levels in ovarian
cancer indicate an association between CCAT2 expres-
sion levels and clinicopathological features of ovarian
cancer patients. Furthermore, CCAT2 knockdown
markedly suppresses cell proliferation, migration and
invasion of ovarian carcinoma cells (Huang et al. 2016).
Considering the association between CCAT2 dysregu-
lation and ovarian cancer, we investigated whether DNC,
Oxa or a combination of these have the potential to lower
the level of expression of this lncRNA. Encouragingly,
we found that Oxa and DNC reduce CCAT2 expression.
We have also demonstrated the synergistic effect of com-
binatorial treatment compared to each of the drugs.
It has recently been reported that AB073614 is upreg-
ulated as a new candidate for lncRNA in a significant
percentage of ovarian cancer tissues compared to its
normal counterparts. Furthermore, the relationship be-
tween high expression of AB073614 and tumorigenic
properties of ovarian cancer cells has been documented.
In vivo experiment also revealed that knockdown
AB073614 suppresses the proliferation of OVCAR3
cells, suggesting the oncogenic function of AB073614
in the development of ovarian cancer (Cheng et al. 2015).
Our results represented that the effect of Oxa on
ABO73614 expression reduction was more than DNC
Table 3 (continued)
Name Condition Fold
change
P value compare
to control
P value compare
to DNC 48 h
P value compare
to Oxa 48 h
Up or
downregulation
Oxa 24 h .56 .048 – – Down
DNC 48 h .76 .37 – – Down not significant
Oxa 48 h .57 .04 – – Down
Combination 48 h .2 .005 .022 .104 Down
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after 48 h. As expected, the maximum inhibitory effect
observed with combination therapy was higher than
monotherapy.
ANRIL, the lncRNA with the same location as the
p14, p15 and p16 genes, plays key roles in cell cycle
regulation and apoptosis (Meryet-Figuière et al. 2016).
Numerous studies have also demonstrated the correla-
tion of ANRIL expression with different human malig-
nancies (Pasmant et al. 2011). In the context of these
data, and recent studies have shown a significant asso-
ciation between ANRIL and ovarian cancer expression
(Mercer et al. 2009), in the current work, we evaluated
the proposed inhibition of ANRIL expression levels in
OVCAR3 cells by DNC, Oxa or a combination thereof.
Our results represent more inhibition of Oxa than DNC
or combination therapy.
BC200 is an lncRNA that specifically expressed in
the human nervous system (Mercer et al. 2009). The
expression of BC200 is significantly reduced in ovarian
cancer tissues and can be used as a potential diagnostic
marker. In addition, low expression of BC200 can in-
duce proliferation of ovarian cancer cells and inhibit
their sensitivity to carboplatin (Wu et al. 2016).
Considering the diagnostic and therapeutic potential of
BC200, the effect of DNC, Oxa and combination of them
on the expression level of this lncRNAwas examined. In
compression DNC with Oxa, we observed greater effect
of Oxa in upregulating of BC200 in OVCAR3 cells.
However, combination of both compound exerted syner-
gistic effect in increasing BC200 expression level.
It has been shown that FAL1, a recently identified
lncRNA, is overexpressed in various human cancers. It
has also been found that FAL1 is enhanced in 38% of
ovarian cancer cases and associated with a shorter sur-
vival time. In an attempt to test the effect of DNC, Oxa
and a combination of these on FAL1 expression inhibi-
tion, we found that Oxa had a greater inhibitory effect
than DNC 48 h after treatment. More importantly, the
combination of both agents synergistically reduces the
level of FAL1 expression.
MALAT1, one of the first identified cancer-related
lncRNAs, contributes to the initiation and progression
of many types of cancers including ovarian cancer
(Dong et al. 2015). Silencing of MALAT1 has attenuat-
ed the proliferation and invasion of osteosarcoma cell
and suppressed its metastasis behavior. Moreover, over-
expression of this lncRNA has been reported in meta-
static bladder tumors but not in non-metastasized ones
(Ying et al. 2012). Although mechanism of action of
MALAT1 in ovarian cancer has not been clearly
understood, its dysregulation has been shown in
ovarian cancer cells with divergent metastatic poten-
tials, which is in agreement with its metastatic role
reported in other types of cancers (Liu et al. 2013).
On the basis of reported data about MALAT1, we
attempted to identify the effect of DNC, Oxa and
combination of them on modulating MALAT1 ex-
pression level. Our data displayed that the inhibitory
effect of Oxa was higher than DNC. We also found
that combination of DNC and Oxa has synergistically
downregulated MALAT1.
The role of XIST as a tumor suppressor lncRNA has
been described in several malignancies including ovarian
cancer. In ovarian cancer cell lines, XIST expression
decrease has been correlated with a shorter free interval.
In addition, a reduced expression of XIST in several
ovarian cancer cell lines was associated with an increased
susceptibility to paclitaxel resistance (Huang et al. 2002).
Since, targeting this lncRNA in cancer therapy may be an
appropriate alternative. In this sense, we questioned
whether DNC, Oxa or combination of them could effec-
tively increase the expression of XIST in OVCAR3 cells.
Unexpectedly, neither DNC and Oxa, nor combination of
them affect the expression of XIST in OVCAR3 cells.
Conclusion
Overall, our results showed that dendrosome increased
the solubility of curcumin and its entry into cells without
the significant toxic effect as a carrier (Mirgani et al.
2014b; Tahmasebi Birgani et al. 2015). Our results
demonstrated the potential of DNC alone or in combi-
nation with Oxa in ovarian cancer treatment. Besides,
encouraging results from combination of DNC with
Oxa highlight the importance of such combinatorial
approaches in cancer therapy improvement. However,
more detailed studies are needed to substantiate the
exact mechanisms underlying the effects of these mo-
dalities both in vitro and in vivo.
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